 Nuclear Medicine Market Insights, Competitive Landscape, and Market Forecast - 2033
The nuclear medicine market is witnessing significant growth as healthcare systems increasingly rely on advanced imaging and targeted therapies to improve patient outcomes. Nuclear medicine uses sm... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe nuclear medicine market is witnessing significant growth as healthcare systems increasingly rely on advanced imaging and targeted therapies to improve patient outcomes. Nuclear medicine uses small amounts of radioactive materials to diagnose and treat a variety of diseases, offering highly precise and minimally invasive solutions. Its role has expanded considerably in recent years, particularly in oncology, cardiology, and neurology, where accurate diagnosis and personalized treatment are critical. Continuous advancements in radiopharmaceuticals and imaging technologies are strengthening the position of nuclear medicine as a cornerstone of modern healthcare practices.Market Insights The global nuclear medicine market is expected to reach 22.3 bn in 2026 and is projected to grow to 46.2 bn by 2033, registering a CAGR of 11.00% over the forecast period. This growth reflects increasing adoption of nuclear imaging techniques and therapeutic procedures across healthcare facilities worldwide. The rising burden of chronic diseases, combined with ongoing innovations in diagnostic imaging and targeted radionuclide therapies, is driving demand. In addition, favorable regulatory support and increased investments in nuclear medicine research are accelerating market expansion. Market Drivers A major factor driving the nuclear medicine market is the increasing prevalence of cancer and other chronic conditions. Nuclear imaging techniques such as PET and SPECT enable early detection and accurate disease monitoring, improving clinical decision-making and patient outcomes. Additionally, cardiovascular and neurological disorders are becoming more common, further boosting demand for advanced diagnostic tools. Technological advancements in radiopharmaceutical development are also contributing significantly to market growth. The emergence of targeted therapies, including alpha and beta emitters, is enhancing treatment effectiveness while minimizing side effects. The aging global population, which is more prone to chronic illnesses, is another important driver. Furthermore, the integration of digital technologies and artificial intelligence in imaging systems is improving efficiency and diagnostic precision. Business Opportunity The nuclear medicine market offers strong growth opportunities for industry participants. Increasing focus on personalized healthcare is creating demand for innovative radiopharmaceuticals designed for specific patient profiles. Emerging markets are particularly attractive due to expanding healthcare infrastructure and rising awareness about advanced diagnostic solutions. There is also growing interest in expanding the application scope of nuclear medicine beyond traditional uses. Developments in theranostics are enabling combined diagnostic and therapeutic approaches, offering comprehensive solutions for disease management. Companies investing in research and development to introduce new isotopes, imaging systems, and hybrid technologies are expected to benefit from significant growth prospects. Strategic partnerships and acquisitions are further enabling market players to strengthen their global footprint and enhance their product offerings. Region Analysis North America continues to lead the nuclear medicine market, supported by well-established healthcare infrastructure, high adoption of advanced technologies, and strong investment in research and innovation. The region also benefits from favorable reimbursement policies and the presence of key industry players. Europe represents another significant market, driven by increasing government support and rising adoption of nuclear medicine procedures. The region is also experiencing growth due to a strong focus on improving diagnostic accuracy and patient care. Asia Pacific is expected to register the fastest growth during the forecast period. Factors such as rapid economic development, increasing healthcare expenditure, and growing awareness about early disease detection are driving demand in this region. Countries like China and India are making substantial investments in healthcare infrastructure, contributing to market expansion. Latin America and the Middle East & Africa are gradually emerging as promising markets. Improvements in healthcare access and infrastructure, along with increasing adoption of advanced diagnostic technologies, are supporting steady growth in these regions. Key Players • Advanced Accelerator Applications • Norgine B.V. • Blue Earth Diagnostics Ltd. • Curium Pharma • Digirad Corporation • Jubilant Radiopharma • Karyopharm • Lantheus Holdings, Inc. • Northstar Nuclear Medicine • Precirix NV • Sinotau Pharmaceuticals • Solcom • Zionexa • Cardinal Health • Bracco Diagnostic Inc. Segmentation By Product Type: • Diagnostics o Single Photon Emission Computed Tomography (SPECT) o Positron Emission Tomography (PET) • Therapeutics o Alpha Emitters o Beta Emitters o Brachytherapy By Application: • Cardiology • Neurology • Oncology • Thyroid • Lymphoma • Other Application By End User: • Hospitals & Clinics • Diagnostic Centres • Others By Geographic Coverage: • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Nuclear Medicine Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Nuclear Medicine Market Outlook, 2020 - 2033 3.1. Global Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 3.1.1. Diagnostics 3.1.1.1. Single Photon Emission Computed Tomography (SPECT) 3.1.1.2. Positron Emission Tomography (PET) 3.1.2. Therapeutics 3.1.2.1. Alpha Emitters 3.1.2.2. Beta Emitters 3.1.2.3. Brachytherapy 3.2. Global Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 3.2.1. Cardiology 3.2.2. Neurology 3.2.3. Oncology 3.2.4. Thyroid 3.2.5. Lymphoma 3.2.6. Other 3.3. Global Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 3.3.1. Hospitals & Clinics 3.3.2. Diagnostic Centres 3.3.3. Others 3.4. Global Nuclear Medicine Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Latin America 3.4.5. Middle East & Africa 4. North America Nuclear Medicine Market Outlook, 2020 - 2033 4.1. North America Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 4.1.1. Diagnostics 4.1.1.1. Single Photon Emission Computed Tomography (SPECT) 4.1.1.2. Positron Emission Tomography (PET) 4.1.2. Therapeutics 4.1.2.1. Alpha Emitters 4.1.2.2. Beta Emitters 4.1.2.3. Brachytherapy 4.2. North America Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 4.2.1. Cardiology 4.2.2. Neurology 4.2.3. Oncology 4.2.4. Thyroid 4.2.5. Lymphoma 4.2.6. Other 4.3. North America Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 4.3.1. Hospitals & Clinics 4.3.2. Diagnostic Centres 4.3.3. Others 4.4. North America Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.4.1. U.S. Nuclear Medicine Market Outlook, by Product Type, 2020-2033 4.4.2. U.S. Nuclear Medicine Market Outlook, by Application, 2020-2033 4.4.3. U.S. Nuclear Medicine Market Outlook, by End User, 2020-2033 4.4.4. Canada Nuclear Medicine Market Outlook, by Product Type, 2020-2033 4.4.5. Canada Nuclear Medicine Market Outlook, by Application, 2020-2033 4.4.6. Canada Nuclear Medicine Market Outlook, by End User, 2020-2033 4.5. BPS Analysis/Market Attractiveness Analysis 5. Europe Nuclear Medicine Market Outlook, 2020 - 2033 5.1. Europe Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 5.1.1. Diagnostics 5.1.1.1. Single Photon Emission Computed Tomography (SPECT) 5.1.1.2. Positron Emission Tomography (PET) 5.1.2. Therapeutics 5.1.2.1. Alpha Emitters 5.1.2.2. Beta Emitters 5.1.2.3. Brachytherapy 5.2. Europe Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 5.2.1. Cardiology 5.2.2. Neurology 5.2.3. Oncology 5.2.4. Thyroid 5.2.5. Lymphoma 5.2.6. Other 5.3. Europe Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 5.3.1. Hospitals & Clinics 5.3.2. Diagnostic Centres 5.3.3. Others 5.4. Europe Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.4.1. Germany Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.2. Germany Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.3. Germany Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.4. Italy Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.5. Italy Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.6. Italy Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.7. France Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.8. France Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.9. France Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.10. U.K. Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.11. U.K. Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.12. U.K. Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.13. Spain Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.14. Spain Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.15. Spain Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.16. Russia Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.17. Russia Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.18. Russia Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.19. Rest of Europe Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.20. Rest of Europe Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.21. Rest of Europe Nuclear Medicine Market Outlook, by End User, 2020-2033 5.5. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Nuclear Medicine Market Outlook, 2020 - 2033 6.1. Asia Pacific Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 6.1.1. Diagnostics 6.1.1.1. Single Photon Emission Computed Tomography (SPECT) 6.1.1.2. Positron Emission Tomography (PET) 6.1.2. Therapeutics 6.1.2.1. Alpha Emitters 6.1.2.2. Beta Emitters 6.1.2.3. Brachytherapy 6.2. Asia Pacific Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 6.2.1. Cardiology 6.2.2. Neurology 6.2.3. Oncology 6.2.4. Thyroid 6.2.5. Lymphoma 6.2.6. Other 6.3. Asia Pacific Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 6.3.1. Hospitals & Clinics 6.3.2. Diagnostic Centres 6.3.3. Others 6.4. Asia Pacific Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.4.1. China Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.2. China Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.3. China Nuclear Medicine Market Outlook, by End User, 2020-2033 6.4.4. Japan Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.5. Japan Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.6. Japan Nuclear Medicine Market Outlook, by End User, 2020-2033 6.4.7. South Korea Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.8. South Korea Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.9. South Korea Nuclear Medicine Market Outlook, by End User, 2020-2033 6.4.10. India Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.11. India Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.12. India Nuclear Medicine Market Outlook, by End User, 2020-2033 6.4.13. Southeast Asia Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.14. Southeast Asia Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.15. Southeast Asia Nuclear Medicine Market Outlook, by End User, 2020-2033 6.4.16. Rest of SAO Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.17. Rest of SAO Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.18. Rest of SAO Nuclear Medicine Market Outlook, by End User, 2020-2033 6.5. BPS Analysis/Market Attractiveness Analysis 7. Latin America Nuclear Medicine Market Outlook, 2020 - 2033 7.1. Latin America Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 7.1.1. Diagnostics 7.1.1.1. Single Photon Emission Computed Tomography (SPECT) 7.1.1.2. Positron Emission Tomography (PET) 7.1.2. Therapeutics 7.1.2.1. Alpha Emitters 7.1.2.2. Beta Emitters 7.1.2.3. Brachytherapy 7.2. Latin America Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 7.2.1. Cardiology 7.2.2. Neurology 7.2.3. Oncology 7.2.4. Thyroid 7.2.5. Lymphoma 7.2.6. Other 7.3. Latin America Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 7.3.1. Hospitals & Clinics 7.3.2. Diagnostic Centres 7.3.3. Others 7.4. Latin America Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.4.1. Brazil Nuclear Medicine Market Outlook, by Product Type, 2020-2033 7.4.2. Brazil Nuclear Medicine Market Outlook, by Application, 2020-2033 7.4.3. Brazil Nuclear Medicine Market Outlook, by End User, 2020-2033 7.4.4. Mexico Nuclear Medicine Market Outlook, by Product Type, 2020-2033 7.4.5. Mexico Nuclear Medicine Market Outlook, by Application, 2020-2033 7.4.6. Mexico Nuclear Medicine Market Outlook, by End User, 2020-2033 7.4.7. Argentina Nuclear Medicine Market Outlook, by Product Type, 2020-2033 7.4.8. Argentina Nuclear Medicine Market Outlook, by Application, 2020-2033 7.4.9. Argentina Nuclear Medicine Market Outlook, by End User, 2020-2033 7.4.10. Rest of LATAM Nuclear Medicine Market Outlook, by Product Type, 2020-2033 7.4.11. Rest of LATAM Nuclear Medicine Market Outlook, by Application, 2020-2033 7.4.12. Rest of LATAM Nuclear Medicine Market Outlook, by End User, 2020-2033 7.5. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Nuclear Medicine Market Outlook, 2020 - 2033 8.1. Middle East & Africa Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 8.1.1. Diagnostics 8.1.1.1. Single Photon Emission Computed Tomography (SPECT) 8.1.1.2. Positron Emission Tomography (PET) 8.1.2. Therapeutics 8.1.2.1. Alpha Emitters 8.1.2.2. Beta Emitters 8.1.2.3. Brachytherapy 8.2. Middle East & Africa Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 8.2.1. Cardiology 8.2.2. Neurology 8.2.3. Oncology 8.2.4. Thyroid 8.2.5. Lymphoma 8.2.6. Other 8.3. Middle East & Africa Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 8.3.1. Hospitals & Clinics 8.3.2. Diagnostic Centres 8.3.3. Others 8.4. Middle East & Africa Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.4.1. GCC Nuclear Medicine Market Outlook, by Product Type, 2020-2033 8.4.2. GCC Nuclear Medicine Market Outlook, by Application, 2020-2033 8.4.3. GCC Nuclear Medicine Market Outlook, by End User, 2020-2033 8.4.4. South Africa Nuclear Medicine Market Outlook, by Product Type, 2020-2033 8.4.5. South Africa Nuclear Medicine Market Outlook, by Application, 2020-2033 8.4.6. South Africa Nuclear Medicine Market Outlook, by End User, 2020-2033 8.4.7. Egypt Nuclear Medicine Market Outlook, by Product Type, 2020-2033 8.4.8. Egypt Nuclear Medicine Market Outlook, by Application, 2020-2033 8.4.9. Egypt Nuclear Medicine Market Outlook, by End User, 2020-2033 8.4.10. Nigeria Nuclear Medicine Market Outlook, by Product Type, 2020-2033 8.4.11. Nigeria Nuclear Medicine Market Outlook, by Application, 2020-2033 8.4.12. Nigeria Nuclear Medicine Market Outlook, by End User, 2020-2033 8.4.13. Rest of Middle East Nuclear Medicine Market Outlook, by Product Type, 2020-2033 8.4.14. Rest of Middle East Nuclear Medicine Market Outlook, by Application, 2020-2033 8.4.15. Rest of Middle East Nuclear Medicine Market Outlook, by End User, 2020-2033 8.5. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Advanced Accelerator Applications 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Norgine B.V. 9.4.3. Blue Earth Diagnostics Ltd. 9.4.4. Curium Pharma 9.4.5. Digirad Corporation 9.4.6. Jubilant Radiopharma 9.4.7. Karyopharm 9.4.8. Lantheus Holdings, Inc. 9.4.9. Northstar Nuclear Medicine 9.4.10. Precirix NV 9.4.11. Sinotau Pharmaceuticals 9.4.12. Solcom 9.4.13. Zionexa 9.4.14. Cardinal Health 9.4.15. Bracco Diagnostic Inc. 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（環境・エネルギー）の最新刊レポート
Fairfield Market Research社の エネルギー・天然資源分野 での最新刊レポート
本レポートと同じKEY WORD（nuclear）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
